Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Richard D. Press et al.|Cancer Cell|2014Cited by 366
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibAndreas Hochhaus, H. Kantarjian, Michele Baccarani et al.|Leukemia|2008Cited by 354
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Ruben A. Mesa et al.|Haematologica|2013Cited by 162
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Jeffrey Tyner, Beth Wilmot et al.|Blood|2019Cited by 84